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Abstract: Head and neck squamous cell carcinoma (HNSCC) remains one of the most aggressive malignancies, 
characterized by limited therapeutic success and poor outcome. Despite continuous development of novel therapeutic 
strategies, disease-free survival in patients with advanced HNSCC has not been improved during the last 30 years. 
Evidently, a deeper understanding is needed of the molecular mechanisms underlying both intrinsic and acquired 
HNSCC cell resistance to currently existing therapeutic approaches. Proteome analysis is a powerful method which can 
provide deep insight into the molecular basis underlying HNSCC cell survival despite cytotoxic anti-tumor treatment 
(chemo-, radiotherapy). Evaluation of the protein profiles of cells obtained from locally recurrent or metastatic tumors can 
allow researchers to identify key protein players which regulate the HNSCC response to therapy. Additionally, subcellular 
fractionation and isolation of various cell organelles followed by proteomic analysis can provide data about intracellular 
protein localization, translocation and function following anti-cancer therapy. This review article discusses the protein 
patterns in HNSCC cells responsible for the radio- and chemo-resistance of these tumors and which result in the 
carcinoma cell survival and HNSCC recurrence.  
Keywords: Head and neck squamous cell carcinoma (HNSCC), Proteomics, Biomarker, Therapeutic target, 
Treatment resistance. 
INTRODUCTION 
Head and neck squamous cell carcinoma (HNSCC) 
is the sixth most common cancer worldwide and is still 
responsible for a quarter of a million deaths annually 
[1]. Overall, HNSCC accounts for more than 550,000 
cases annually worldwide [2]. Males are affected 
significantly more than females with a ratio ranging 
from 2:1 to 4:1. The incidence rate in males exceeds 
20 per 100,000 in regions of France, Hong Kong, the 
Indian subcontinent, central and eastern Europe, 
Spain, Italy, Brazil and among African Americans in the 
United States. Mouth and tongue cancers are more 
common in the Indian subcontinent, nasopharyngeal 
cancer is more common in Hong Kong, and pharyngeal 
and/or laryngeal cancers are more common in other 
populations [3, 4]. HNSCC is traditionally associated 
with older men who smoke and consume alcohol. 
Alcohol and tobacco use (including smokeless tobacco, 
sometimes called “chewing tobacco” or “snuff”) are the 
two most important risk factors for HNSCC, especially 
for cancers of the oral cavity, oropharynx, 
hypopharynx, and larynx [5, 6]. At least 75% of 
HNSCCs are caused by tobacco and alcohol use [7, 8]. 
Infection with cancer-causing types of human  
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papillomavirus (HPV), especially HPV-16, is also a risk 
factor for some types of HNSCC, particularly 
oropharyngeal cancers that involve the tonsils or the 
base of the tongue [9]. The incidence of oropharyngeal 
cancers caused by HPV infection is increasing 
worldwide, while the incidence of oropharyngeal 
cancers related to other causes is falling [3, 10]. 
Although methods of HNSCC prevention and 
diagnosis are continuously being developed, many 
patients are diagnosed only at advanced stages of 
tumor development. This markedly reduces the arsenal 
of anti-tumor treatments available and worsens clinical 
outcome. Surgery, chemotherapy, and radiation remain 
the mainstay of patient care [11]. Despite ongoing 
improvement in traditional treatments, the long-term 
survival rate, which is 50% at five years after diagnosis, 
has remained unaltered over the past thirty years [12]. 
HNSCC tumor resistance to therapy is the major cause 
of cancer-related deaths, because the disease 
progresses even after all possible anti-tumor 
therapeutic options have been tried. It is therefore 
necessary to elucidate the factors which influence the 
efficacy of various treatment approaches (radio- and 
chemotherapy, targeted agents). Definition of the 
molecular pathways mediating constitutive or acquired 
cancer aggressiveness and therapy insensitivity would 
contribute to the development of novel diagnostic, 
predictive markers and therapeutic targets. HNSCC is 
a heterogeneous tumor consisting of multiple cancer 
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cell subpopulations, so it is necessary to identify the 
cell subpopulations responsible for HNSCC treatment 
resistance and recurrence and then to elucidate the 
molecular properties of these cells. Currently existing 
proteome-based methods can help to clarify how 
intracellular and intratumoral signaling pathways are 
altered in the most resistant HNSCCs. 
PROTEOMICS IS A TOOL FOR PROTEIN 
IDENTIFICATION 
Genetic analysis is widely used in cancer research 
to identify altered genes predicting either a 
predisposition to cancer development, to disease 
progression or to the probable tumor response to 
therapy and thus clinical outcome. However, nucleic 
acids do not provide full information about the 
intracellular or intratumoral molecular networks 
associated with these processes. In contrast, 
oncoproteomics can determine which molecular 
pathways are affected and are implicated in tumor 
development and progression, and thus which 
molecules could be targeted to improve clinical 
outcome. Currently, researchers possess a variety of 
proteome-related approaches that can be applied 
depending amongst other things on the aim of the 
investigation, on the type, size or volume of the 
samples, and on the concentrations of the proteins in 
the samples. 
Proteomic analysis aims to study the structure of 
proteins (structural proteomics), to determine protein 
expression in the compared biological samples 
(differential proteomics) and to elucidate molecular 
mechanisms underlying disease progression or other 
intracellular/intratumoral events (functional proteomics) 
[13]. In the development of cancer-related biomarkers 
and therapeutic targets, differential and functional 
proteomics are the most important and actively used 
approaches. There are two major technical directions in 
proteomics: the gel-based and the gel-free methods. 
Although gel-based techniques followed by mass 
spectrometry are laborious and time-consuming, they 
identify a wide range of proteins that are specifically or 
differentially expressed in the samples of interest. Both 
gel-based approaches, namely one- and two-
dimensional gel electrophoresis (1-D and 2-D GE), can 
identify proteins of different molecular weights, from 10 
kDa to more than 300 kDa [14]. In some cases use of 
1-D GE can overcome limitations observed during the 
performance of 2-D-based proteomics. Thus, 1-D SDS 
PAGE coupled with liquid chromatography-mass 
spectrometry (LC-MS) helped to identify low abundant 
proteins with extremely basic or acidic pH, and which 
were not identified using 2-D gels [14;15]. Despite clear 
visualization of the differences in expression of proteins 
and their modifications, 2-D GE has some limitations: 
proteins are usually poorly detected if they are present 
in low abundance, or have an extremely basic pH, or a 
molecular mass less than 10 kDa or greater than 200 
kDa. Furthermore, inadequate sample solubilisation 
adds further difficulties in evaluating protein expression 
and identifying the spots selected in the 2-D gels. 
However, standard and differential 2-D GEs followed 
by mass spectrometry are still widely used by 
researchers to detect proteins responsible for disease 
progression or for clinical outcome in cancer patients 
[16, 17].  
Since gel-based methods have a number of 
limitations, gel-free approaches were developed and 
mass spectrometry became a core technology of 
proteomics [16]. Gel-free proteomics does not require 
protein separation prior to digestion and peptides are 
fractionated via LC, and it is also possible to use a 
combination of gel-based separation of proteins and 
LC-MS-MS. Furthermore, as recently shown, mass 
spectrometry methods can be combined and the use of 
MALDI and ESI mass spectrometry substantially 
improves protein identification in samples [18].  
Simultaneous analysis of different proteins and their 
expression can be evaluated using protein microarrays 
and MALDI imaging [14, 19]. The protein microarray or 
protein chip is a proteomic tool which allows fast and 
effective screening of thousands of different proteins. 
Forward-phase protein array analysis is often 
performed using fluorophore-labelled antibodies to 
capture proteins and to compare them, similarly to the 
2-D DIGE technique [14]. In contrast, the reverse-
phase protein array immobilizes the protein samples on 
a surface, followed by application of antibodies to 
detect specific epitopes. The protein microarray is very 
useful and attractive for biomarker discovery and for 
fast screening of proteins which are candidates to 
become biomarkers.  
MALDI imaging is another new and attractive 
method to compare protein expression in different 
tissues [19]. Direct application of MALDI-TOF-MS in 
tissue slices does not require tissue homogenization 
and the method allows not only protein identification 
but can also visualize protein distributions both in the 
tumor and in the adjacent normal tissues. MALDI 
imaging has other strengths, for example it can be 
used in principle to evaluate protein patterns at the 
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subcellular level in organelles [20, 21]. Despite its high 
capacity to evaluate protein expression and alterations 
in molecular pathways directly in the tumor tissues, this 
method does have pronounced limitations. Firstly, the 
time needed to prepare and process fresh frozen or 
formalin-fixed paraffin-embedded tumor tissues for 
MALDI imaging can markedly reduce the efficacy of 
protein identification. Secondly, the so-called 
phenomenon of ion (ionization) suppression occurs in 
tumor tissues analyzed by use of MALDI imaging [19]; 
it is not specific for MALDI imaging and can accompany 
any mass spectrometric analysis. It can compromise 
the results of MALDI imaging analysis because one 
protein may be more easily ionized than another that is 
present in the same tumor tissue [19, 22]. Further 
validation of the proteins identified by MALDI imaging is 
essential, and can be carried out by a range of different 
methods, including immunohistochemistry, ELISA, flow 
cytometry, and immunofluorescence analysis. 
SAMPLES FOR PROTEOME ANALYSIS 
HNSCC Cell Lines: In Vitro Samples for the Study 
of HNSCC Treatment Resistance 
The selection of samples for proteome-based 
discovery of predictive biomarkers or therapeutic 
targets is the most critical point in translational cancer 
research. In general, HNSCC sampling for proteomic 
approaches can be conducted in either of two 
directions: pre-clinical and clinical. Pre-clinical samples 
include material obtained in vitro or in vivo.  
In vitro cell line models, either primary or 
immortalized, allow the molecular mechanisms of 
cancer cell resistance to chemotherapeutic agents 
and/or ionizing radiation to be investigated 
comprehensively. Immortalized cell lines are 
particularly advantageous for the identification of 
proteins associated with cancer cell treatment 
resistance because their cellular composition is 
homogeneous. In contrast to tumor tissues, the cell 
lines do not contain the several additional cell types 
that belong to the connective tissues, the blood or the 
immune system. The researcher can therefore be 
assured that any proteins identified by use of 
proteomics-based methods are specific only for the 
cancer cells and are therefore implicated in intracellular 
pathways associated with functions occuring in the 
cancer cells. Next, immortalized carcinoma cell lines 
are widely used to obtain cells with acquired treatment 
resistance, which are optimal for studies aimed at 
elucidating the molecular mechanisms related to the 
treatment resistance or better response of carcinoma 
cells. Differences in the protein patterns found in 
treatment-resistant and treatment-sensitive carcinoma 
cells are restricted to the mechanisms of therapy 
resistance. For example, recent reports on HNSCC 
radiation resistance showed clear differences in the 
protein profiles of radio resistant HNSCC cells as 
compared to radiation sensitive cells [23-25]. Both 
research groups indicated that radiation resistant 
HNSCC cells were characterized by up-regulation of 
proteins participating in the DNA damage response, 
cell cycle regulation, cell adhesion, migration and 
motility. All these intracellular processes delineate 
cancer stem cell (CSC)-specific molecular signatures. It 
has also recently been shown that CSCs are 
characterized by activation of pathways related to the 
DNA damage response [26, 27]. Thus, expression of 
ATM, Chk1 and Chk2 DNA repair and cell cycle-
associated proteins are affected in CSCs, resulting in 
CSC resistance to DNA-damaging agents (e.g., 
radiotherapy, platinum compounds). Furthermore, 
proteomic-based studies aiming to elucidate the 
molecular background for radiation or chemo 
resistance have shown that therapy resistant 
carcinoma cells are characterized by up-regulation of 
scavengers of reactive oxygen species (ROS), which 
also contribute to the treatment-caused DNA damage 
[25, 28]. Since key proteins regulating carcinoma cell 
resistance to therapeutic approaches have been 
identified, it is possible to develop novel therapeutic 
agents inhibiting either expression or activity of these 
proteins. It is believed that concomitant use of 
conventional therapeutic approaches and compounds 
targeting activated pro-survival pathways in carcinoma 
cells can markedly improve therapy outcome in cancer 
patients.  
Since radio- and chemo-resistant cell lines are 
usually enriched for CSCs, it was logical to suggest 
that CSCs possess the highest expression of the ROS 
scavengers. Indeed, recent reports have clearly 
demonstrated that due to the over expression of ROS 
scavengers, CSCs reveal very low ROS concentrations 
compared to the bulk of tumor cells and even to normal 
non-malignant cells [29]. This fact is a partial 
explanation for the reduced DNA damage seen in 
treatment resistant CSCs.  
Unfortunately, the exact mechanisms of CSC 
therapy resistance are still poorly understood. A 
possible way forward is the recently described idea of 
isolating CSCs from in vitro cultivated cell lines and 
examining them by proteomic analysis to obtain a list of 
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the proteins associated with treatment resistance and 
with enhanced pro-survival activities [30, 31]. 
Furthermore, subcellular fractionation of cultured CSCs 
could be used to improve our knowledge of the 
subcellular localization and translocation of these 
proteins. Indeed, our research group has recently 
demonstrated that enhanced Rac1 expression in the 
nuclei of HNSCC cells can predict a lower sensitivity of 
HNSCC cells to ionizing radiation and platinum 
compounds [24]. Similarly, EGFR translocation to the 
nuclei is associated with an enhancement of DNA 
repair and with consequent cell resistance to DNA-
damaging agents [32;33]. Attenuation of Rac1 
expression and inhibition of its activity in chemo-radio 
resistant HNSCC cells improved cytotoxic effects of 
ionizing radiation and cisplatin [24]. 
Since there is no a single opinion as to which 
membrane proteins can be used as markers for HNSC 
CSCs, membrane proteomics is under deep 
investigation. Analysis of the membrane proteins 
underlying differences in molecular properties between 
HNSCC spheroid-forming and adherent cells has 
demonstrated that two types of network are affected in 
spheroid-forming cells enriched for CSCs, these are: 
the EGFR - CD44 - HSP70 - HSP90 and the integrin 
alpha-6 - integrin beta-4 - SLC3A2 pathways [34]. 
These data correspond to our own data, which show 
dysregulation of these pathways in radio- and chemo-
resistant HNSCC cell lines enriched for CD44-positive 
CSCs [23, 35]. It is likely that there is no unique or 
single marker identifying HNSC CSCs; it is more likely 
that CSCs are characterized by expression of several 
different markers associated with their functional 
capacities.  
Nowadays exosomes are organelles of interest 
which can be studied in HNSCC by use of proteomics 
[36]. Identification of the protein profiles of these 
extracellular organelles is more useful than analyzing 
the cellular or tumoralsecretomes. The main advantage 
is that the cellular secretome contains not only proteins 
secreted by the carcinoma cells, but also enzymes 
deriving from cells which are dying or damaged during 
cultivation under stress conditions. Isolation of the 
exosomes can help to avoid contamination with non-
exosome-specific proteins and makes proteomic-based 
identification of the secreted proteins more accurate. 
Exosomal proteins can influence the activity of 
intratumoral immune T-cells, thus supporting the 
immune escape of tumor cells [37]. These proteins can 
also enhance the invasive capacities of carcinoma cells 
[38], they can change the migration of endothelial cells 
and they can serve as pro-angio- and vasculogenic 
agents [35]. One further reason why protein profiling of 
exosomes should be an issue of interest is that 
exosomal proteins can serve as a source of biomarkers 
that can be found in the biological fluids of cancer 
patients (plasma, serum, saliva).  
Experimental In Vivo Samples to Study HNSCC 
Progression 
Despite the fact that almost all studies identifying 
perturbations in molecular pathways associated with 
the HNSCC response to chemo- and radiotherapy were 
performed using carcinoma cell lines, in vivo xenograft 
models can also be utilized. Experimental animal 
models allow determination of how the response to 
therapy is regulated within the tumor. In order to know 
why HNSCC patients respond differently to 
combinations of radiotherapy and cetuximab, xenograft 
tumors were investigated using 2D-DIGE followed by 
MALDI-TOF/TOF [39]. It was found that cetuximab 
effectively inhibited the growth of tumors having an 
epithelial phenotype characterized by overexpression 
of epithelial markers (E-cadherin) and decreased 
expression of mesenchymal markers (vimentin and N-
cadherin), whereas HNSCC with mesenchymal 
phenotypes were resistant to this EGFR blocker. 
However, cetuximab failed to enhance the tumor 
response to ionizing radiation if HNSCC with an 
epithelial phenotype had initiated the epithelial-to-
mesenchymal transition programme, accompanied by 
up-regulation of the c-myc protein. In contrast, tumors 
that were initially mesenchymal but had initiated the 
change toward an epithelial phenotype, with c-myc 
down-regulation, showed significant improvement of 
their response to radiation upon treatment with 
cetuximab [39]. Although proteomic analyses can 
identify the perturbed intratumoral proteins, most 
researchers prefer to evaluate protein profiles of 
carcinoma cells using cell lines first and then proceed 
to validate the intratumoral roles of these proteins by 
use of in vivo xenograft models.  
An especially interesting and important research 
area is the use of experimental animal models to 
elucidate the molecular mechanisms underlying the 
metastatic spread of malignant tumors. There are at 
least two possible ways to identify proteins associated 
with tumor metastatic spread: (1) to study protein 
patterns of the xenograft tumors obtained using primary 
or immortalized cell lines with known metastatic 
capacities and (2) to compare the proteomes of tumor 
cells obtained from both primary and secondary 
metastatic tumors. Both methods can provide data 
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about the activated and repressed pathways 
associated with the high metastatic potential of 
malignant tumors. Analysis of the literature shows that 
the first method, using animal models, is widely used 
by researchers to determine the metastasis-related 
proteome, whereas the second approach is preferably 
performed in clinical samples to compare the protein 
patterns of primary and secondary tumors. It has 
recently been reported that the metastatic potential of 
HNSCC depends on the expression of mesenchymal 
markers and CSC-associated proteins (Oct4, ALDH1) 
[40]. These results correspond to our own data 
showing that HNSCC expressing CSC-related proteins 
(Notch1, CD44+/CD24-/ALDH1+) have enhanced 
metastatic abilities [35]. Another report by Huang et al. 
demonstrated that the metastatic abilities of 
nasopharyngeal carcinoma were associated with 
phosphorylation of lysine-rich CEACAM1 co-isolated 
protein (LYRIC) [41]. Indeed, LYRIC is described to be 
a part of the tight junction complex [42]. Since tight 
junctions create an intercellular barrier and an 
intramembrane diffusion fence, reduction of these 
junctions due to LYRIC phosphorylation can initiate 
metastatic processes [43]. Intratumoral identification of 
the proteins associated with the enhancement of 
HNSCC metastatic potential can help clinicians to 
reschedule therapy towards administration of more 
aggressive and toxic treatments. 
Patients’ Material for Evaluation of the HNSCC-
Related Proteome 
A number of clinically relevant samples can be 
obtained from patients for proteomic analyses, and 
used to elucidate the molecular mechanisms 
underlying HNSCC responses to chemo-radiotherapy 
(Figure 1). Evaluation of the protein profiles in such 
tissue samples is a powerful approach, because by 
comparing the protein patterns in malignant tissues and 
healthy mucosa in both primary and secondary tumors, 
and in tumors with good and poor therapy responses, 
one can obtain a long list of putative biomarkers to 
predict treatment outcome in the patients (Table 1). 
Unfortunately, use of biopsy materials obtained from 
cancer patients can sometimes be compromised in the 
protein profiling by tumor heterogeneity, in particular 
because the samples compared derive from tumor 
regions containing different cancer cell subpopulations 
[44]. It is best to increase the number of tissue samples 
examined in order to avoid (or at least to reduce) any 
mistakes in defining protein expression in the tumors 
with different treatment responses or in primary and 
metastatic tumor tissues. Since CSC theory is 
increasing in popularity and can explain tumor 
heterogeneity, researchers try to obtain CSC 
subpopulation(s) from tumor tissues of interest. CSCs 
can be isolated from tumor tissues by a variety of 
methods, including fluorescence (FACS) and magnetic 
(MACS) activated cell sorting, laser cell capture 
microdissection, or three-dimensional spheroid/ 
organoid cell culture. It remains an important challenge 
to determine whether the sets of proteins found in 
CSCs are similar in primary and secondary (metastatic 
or locally relapsed) tumors. The following questions 
need to be answered: are CSCs obtained from 
recurrent or metastatic tissues more aggressive than 
CSCs in primary tumors? If yes, which molecular 
pathways are affected in the more aggressive CSCs? 
Which proteins can indicate CSC aggressiveness? 
Clinicians aiming to be more successful in the 
treatment of HNSCC face several very urgent 
challenges: (1) to identify the key regulator(s) of CSC 
activities in order to to use it (them) as biomarker(s) 
and/or therapeutic target(s) to predict and overcome 
treatment resistance; (2) to find effective ways to image 
the proteins once they have been found; (3) to use 
protein imaging to evaluate the efficacy of treatment in 
eliminating CSCs; (4) to employ protein imaging to 
determine the regions of the malignant tumors which 
contain CSCs and therefore require additional 
treatment by ionizing radiation with higher energy (so 
called LET-painting irradiation); (5) to develop novel 
radiolabeled antibodies targeting CSCs. Zhu et al. 
(2014) recently reported the use of proteomic analysis 
to identify biomarkers and protein networks in 
hypopharyngeal HNSCC [45]. They found that Sp1, c-
myc and p53 crosstalk is implicated in HNSCC 
carcinogenesis and metastatic spread.  
Next, the tumor secretome can provide information 
equally as important as the cellular secretome, about 
the proteins secreted by primary or secondary tumors. 
Proteins identified in the secretome can also be sought 
in biological fluids such as serum, plasma or saliva. 
Despite the very limited published information about 
tumor secretome analysis in HNSCC patients, some 
putative circulating biomarkers have been identified by 
proteomic methods. Thus fascin, found amongst 75 
other proteins in the HNSCC interstitial fluids, has been 
mentioned as a factor discriminating between healthy 
individuals and HNSCC patients [46]. These authors 
confirmed that fascin concentrations are elevated in 
serum obtained from HNSCC patients as compared to 
healthy persons, thus validating fascin’s diagnostic 
value. Additionally, elevated expression of fascin in 
primary HNSCC indicated a higher risk of HNSCC 
metastatic spread [47]. Therefore, this protein can also 
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be considered as a stratification factor for HNSCC 
patients, indicating high and low risks of metastatic 
spread. Fascin has been shown to be implicated in the 
PI3K-Akt-related chemoresistance of breast cancer 
cells [48], therefore it can be assumed that evaluation 
of the intratumoral fascin expression might help to 
predict a possibly reduced chemosensitivity in HNSCC 
patients.  
Since HNSCC tumors can excrete proteins and 
these tumors are located either directly in the oral 
cavity or very near to it, it would be logical to try to 
analyse protein expression in saliva. Similarly as for 
tumor samples, the salivary proteome may be used 
effectively for early detection and monitoring of 
malignant tumors [49-51]. Salivary proteomics is a very 
promising approach to identify HNSCC-related 
biomarkers for the following reasons: sample collection 
is non-invasive, the volume of samples collected is 
unrestricted, and saliva contains a high concentration 
of proteins including those deriving from the tumor and 
its adjacent tissues. Recently it has been shown that 
increased levels of soluble CD44 in saliva help to 
distinguish malignant from benign diseases of the oral 
cavity [52, 53]. A number of other proteins have also 
been reported as potential biomarkers for HNSCC. 
Thus, MRP14, CD59 (protectin), cytokeratin 19 
fragment Cyfra 21-1, M2BP, profilin 1, autoantibodies 
to p53, and cancer antigen 125 were all found in 
malignant lesions in the oral cavity [53, 54]. Such 
proteins, once identified, can be proposed for further 
validation as promising diagnostic tools. Biomarkers 
discovered using salivary proteomics can usually be 
applied for cancer detection, but little is known about 
any relationship between salivary protein profiles and 
treatment outcome in HNSCC patients. To our 
 
Figure 1: Schematic representation of sample collection for proteomic analysis in HNSCC patients. 
Identification of proteins associated with treatment resistance in HNSCC patients can be carried out on samples obtained from the oral cavity 
(saliva) or from the primary or secondary (metastatic) tumors. Tissue pieces obtained from the tumor can be analysed directly by use of MALDI 
imaging mass spectrometry or can be further processed in order to obtain populations of the bulk tumor cells and/or of CSCs. All the types of 
tumor cell subpopulations can be processed to isolate subcellular organelles or to collect secretome. Blood is usually used to obtain plasma and 
serum for proteomics. However, blood could also be used to harvest circulating cancer cells. All the types of HNSCC samples mentioned are 
then processed for protein separation followed by mass spectrometry and bioinformatics analysis. 
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knowledge only one report contains data about a 
possible link between proteins found in the saliva of 
HNSCC patients and the response to DNA-damaging 
agents [55, 56]. Patients with cancer of the oral cavity 
showed alterations in the levels of reactive nitrogen 
species and of antioxidants that could cause alterations 
in the concentrations of salivary free radicals, and thus 
alter the response to treatment, in particular to 
treatment employing DNA-damaging agents. Since 
salivary proteomics is a powerful tool, which provides a 
framework for discriminating between malignant and 
benign disease, and opening new perspectives for 
discovery of biomarkers capable of predicting response 
to treatment, the development of salivary protein 
databases would be very useful for both researchers 
and clinicians. Currently a WEB-site ‘Salivary Proteome 
Knowledge Base’ is being developed 
(http://www.skb.ucla.edu/cgi-bin/hspmscgi-
bin/welcome_c.cgi) and promises to be a platform 
where salivary proteomes can be analysed for protein 
profiles and protein significance.  
Salivary proteomics has a deep relationship with 
serum proteomics. Salivary and serum proteomes 
show very similar alterations in protein expression in 
HNSCC patients [51]. We suggest that serum 
proteomics can be used not only for cancer detection, 
but also for prediction of tumor response and 
evaluation of the tumor damage upon anti-cancer 
treatment [57, 58]. Thus, acute phase proteins 
(fibrinogen, haptoglobin, hepcidin, SAA), complement 
factors (CO3, CO4A), protease inhibitors (AACT, 
ANT3, CYTC, ITIH4), cytokines (CCL13, CXCL7, 
OSTP, PLF4, S10AC) and antibacterial defense factors 
(DEF1, DEF3, DEFB1) have been found in serum 
obtained from HNSCC patients receiving radiotherapy 
[59]. It has also been shown that serum protein profiles 
depend on the dose and volume of irradiation. 
Blood samples intended for proteomic analysis can 
be processed to isolate the circulating tumor cells 
(CTC). Since CTC serve as a factor possessing 
prognostic impact for disease-free survival in HNSCC 
patients, it is logical to assume that evaluation of the 
CTC protein patterns could help to understand the 
molecular mechanisms underlying disease progression 
and tumor response to therapy [60]. Unfortunately, 
CTC is a rare cell subpopulation and only 1 CTC can 
be detected in 1 mL blood [61]. It is therefore a big 
challenge to study protein expression in the small 
protein samples obtained from CTC populations. 
However, the current development of proteomic 
techniques allows analyse of even very small samples 
having low protein concentrations. 
CONCLUSION 
The problem of the effective treatment of malignant 
tumors is very complicated and requires 
comprehensive treatment approaches to protect 
patients from local or distant tumor recurrences. 
Unfortunately, until today a “one-size-fits-all” therapy 
concept is used to manage HNSCC. Since this non-
personalized treatment method cannot effectively 
prevent recurrence, it is logical to suggest that it should 
be replaced by personalized medicine. On the one 
hand, personalized medicine can help to avoid 
overtreatment of HNSCC patients with a lower risk of 
tumor relapse and on the other hand it can accelerate 
therapy schedules in patients having a higher risk of 
HNSCC recurrence. Biomarkers predicting the risk of 
HNSCC relapse after radio- and/or chemotherapy 
should be discovered and introduced into clinical 
practice for better stratification of HNSCC patients. 
Evaluation of the molecular features of HNSCC 
showing different tumor responses to therapy can help 
to identify candidate proteins to become predictive 
biomarkers. Furthermore, determining the proteins 
associated with HNSCC treatment resistance can 
provide the background for development of potential 
therapeutic targets. Novel targeting therapeutics might 
help to repress firstly pathways related to the enhanced 
survival capacities of the HNSCC cells and also other 
mechanisms which protect tumors from ionizing 
radiation and chemotherapeutic compounds. 
Additionally, identification of the molecules responsible 
for tumor resistance to radiotherapy would provide the 
basis to develop imaging methods able to visualize 
tumor regions containing subpopulations of treatment-
resistant cells. Intratumoral imaging can markedly 
improve radiotherapy results because it enables an 
increased dose of irradiation to be applied to the tumor 
regions containing resistant cells, yet concurrently to 
spare the surrounding tissues from radiation damage.  
Proteomics serves as one of the ‘omics’ approaches 
that can be used for development of predictive 
biomarkers and therapeutic targets. Proteomics 
possesses a number of opportunities to process a 
variety of HNSCC samples for protein identification and 
for evaluation of resistance-specific pathways. 
However, correct selection of the samples that should 
be examined using proteomics is an important issue. 
Currently, researchers use both pre-clinical (in vitro and 
in vivo HNSCC samples) and clinical samples (blood, 
serum, plasma, tumor pieces, saliva, primary cell 
culture, isolated CSCs and circulating tumor cells) to 
conduct proteomics. We suggest that concurrent 
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proteomics-based evaluation of the different samples 
could markedly improve identification of the proteins 
associated with HNSCC resistance to treatment.  
Table 1: Proteins Associated with HNSCC Carcinogenesis, Disease Progression and Response to Treatment. Protein 
Functions were taken from the Uni Prot (www.uniprot.org) Database and Provided in the Table 
Sample Protein Protein’s Function Proteome Approach Ref. 
Annexin A1 
Innate and adaptive immune response; epithelial 
differentiation and growth regulation; Ca2+-dependent 
phospholipid-binding proteins; inflammation 
DIGE + MS 
2DE+MS 
[62-64] 
Heat shock protein 
27 
Intracellular signal transduction, negative regulation of 
apoptotic process, positive regulation of angiogenesis, 
immune response 
2DE + MALDI ToF MS [64] 
Lamin A/C 
Negative regulation of apoptosis, cellular response to 
hypoxia, cellular protein metabolic processes, regulation 
of protein localization to nuclei 
2DE + MALDI ToF MS [64] 
Interleukin 1 
receptorantagonist 
Immune and inflammatory response 2DE + MALDI ToF MS [64] 
Serine protease 
inhibitor clade B5 
(serpinB5) 
Extracellular matrix organization, morphogenesis of 
epithelium, negative regulation of endopeptidase activity, 
regulation of epithelial cell proliferation 
2DE + MALDI ToF MS [64] 
Stathmin 1 
Intracellular signal transduction, regulation of 
cytoskeleton organization 
2DE + MALDI ToF MS [63-66] 
Superoxide 
dismutase 2 
Reactive oxygen species metabolic process, regulation 
of mitochondrial membrane potential, activation of MAPK 
activity 
2DE + MALDI ToF MS [64] 
Stratifin (14-3-3 
proteinsigma) 
Positive regulation of cell growth, positive regulation of 
epidermal cell differentiation, regulation of cyclin-
dependent protein serine/threonine kinase activity, signal 
transduction, regulation of apoptosis 
2DE + MS [63;66] 
S100 calcium-binding 
protein A9 
Actin cytoskeleton reorganization, autophagy, 
inflammatory response, innate immune response, 
positive regulation of cell growth, positive regulation of 
NF-kappaB transcription factor activity, regulation of 
integrin biosynthetic process 
2DE+MS [66] 
Actin-related protein 
2/3 complex 
(P21-ARC) 
Structural constituent of cytoskeleton, small GTPase 
mediated signal transduction, ephrin receptor signaling 
pathway 
2DE+MS [66] 
Enolase Glycolysis, small molecule metabolic process  [66] 
Tissue 
Hetero-geneous 
nuclear ribonucleo-
protein K(hnRNPK) 
Positive regulation of receptor-mediated endocytosis, 
RNA processing, RNA splicing, signal transduction 
LC+tandem MS [67] 
Fibrinogen -
chainfragment 
Cellular adhesion, proliferation, and migration of protein 
during carcinogenesis 
MALDI ToF/ToF + 
Mascot identification 
[68] 
Immunoglo-bulin 
gamma-3 chain C 
region 
Innate immune response, complement activation, 
classical pathway 
Nano-LC ESI MS/MS 
+ Mascot identification 
[69] 
Complementcompon
entC4a 
Innate immune response, inflammatory response, 
complement activation 
MALDI ToF/ToF + CID 
and LIFT acquired 
MS/MS 
[69] 
Plasma 
Immunoglo-bulin 
kappachain C region 
Immune response, complement activation, receptor-
mediated endocytosis 
Nano-LC ESI MS/MS 
+ Mascot identification 
[69] 
Heat shock protein 
70 
Stress response, membrane organization, cell cycle 
regulation, 
2DE + MALDI ToF MS [70] 
Soluble form of 
ICAM-1 (sICAM1) 
Regulation of cellular adhesion 2DE + MALDI ToF MS [70] Serum 
Serum amyloid A 
protein (SAA) 
Activation of MAPK activity, positive regulation of cell 
adhesion, receptor-mediated endocytosis 
2DE + MALDI ToF MS [70] 
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FUTURE VIEW 
It is generally accepted that HNSCC is a disease 
with poor prognosis and unfavourable treatment 
outcome, due to the limited tumor response to radio- 
and chemotherapy and which results in early or late 
tumor recurrence. It seems that the currently existing 
management of HNSCC patients should be markedly 
re-directed towards the development of personalized 
medicine. Under the term “personalized medicine” we 
usually understand that each cancer patient should be 
diagnosed and treated individually. Clearly, detecting 
the expression of proteins associated with tumor 
aggressiveness, and with inclination for tumor relapse 
owing to higher survival rates of carcinoma cells, can 
provide oncologists with the information required to 
administer augmented and more effective therapeutic 
schedules. In order to know which proteins are related 
to the tumor’s capacity to survive anti-tumor 
treatments, it is necessary to elucidate the molecular 
profiles of such tumors. Furthermore, clarification of the 
key players in HNSCC aggressiveness can help not 
only to discover novel predictive biomarkers, but also to 
consider these molecules as potential therapeutic 
targets. The pharmaceutical industry in collaboration 
with academic institutions tries to develop novel 
targeting therapeutics (small molecules, antibodies) 
blocking the intracellular pathways which help cells to 
overcome treatment toxicity. However, the majority of 
these agents eliminate only the bulk tumor cells, 
whereas the cells with higher pro-survival abilities 
remain undamaged. It is logical to suggest that the next 
efforts of researchers should be devoted to elucidating 
the molecular patterns of the CSCs responsible for 
disease progression. Furthermore, knowledge about 
CSC specific protein profiles can be used as a 
background to develop imaging techniques visualising 
intratumoral CSC localization. These CSC-based 
imaging techniques can be used by radiation 
oncologists to individualise radiation therapy 
schedules. Thus, it is suggested that in addition to the 
conventional photon-based therapy usually used in the 
treatment of HNSCC, boost proton- or carbon ion-
based radiation therapy could also be applied to 
eliminate CSC agglomerates more effectively. It is 
certain that proteomics can serve as a very powerful 
method to identify the most promising molecular 
candidates for use as predictive biomarkers, and as 
therapeutic and imaging targets.  
KEY ISSUES CONSIDERED IN THE REVIEW 
ARTICLE: 
• HNSCC is a highly aggressive malignant type of 
tumor characterized by an inclination for local 
recurrence despite the use of a variety of anti-
tumor therapeutic approaches, such as surgery, 
radiotherapy, chemotherapy and targeting 
agents. 
• Despite enormous efforts by researchers and 
clinical oncologists, therapy outcomes in HNSCC 
patients have not significantly changed during 
the last three decades. 
• Proteomic analysis can be used to determine the 
molecular mechanisms underlying HNSCC 
chemo- and radioresistance with subsequent 
recurrence after treatment.  
• HNSCC can relapse due to the specific protein 
profiles associated with constitutive or acquired 
chemo- and/or radioresistance in carcinoma 
cells. 
• The protein patterns of radio- and chemo-
resistant carcinoma cells are very similar to the 
protein signatures in CSCs.  
• Correct choice of biological samples for further 
proteomic analysis, whether tumor tissue, 
isolated carcinoma cells and their organelles, 
CSCs, circulating tumor cells, or biological fluids 
(cancer cell or tumor tissue derived secretomes, 
plasma and serum, saliva) can provide a 
framework for biomarker discovery and the 
development of potential therapeutic targets. 
• Prediction of treatment resistance in HNSCC 
patients can provide the basis for re-directing 
treatment schedules towards the use of more 
aggressive treatments.  
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